Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

James D. Doecke, Larry Ward, Samantha C. Burnham, Victor L. Villemagne, Qiao Xin Li, Steven Collins, Christopher J. Fowler, Ekaterina Manuilova, Monika Widmann, Stephanie R. Rainey-Smith, Ralph N. Martins, Colin L. Masters

Research output: Contribution to journalArticlepeer-review

27 Citations (Web of Science)


Background: β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer's disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-efficient, quick and equally valid method to define AD pathology. Methods: Using automated Elecsys® assays (Roche Diagnostics) for Aβ (1-42) (Aβ42), Aβ (1-40) (Aβ40), total tau (tTau) and phosphorylated tau (181P) (pTau), we examined CSF samples from 202 participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing cohort, to demonstrate the concordance with pathological AD via PET imaging. Results: Ratios Aβ42/Aβ40, tTau/Aβ42 and pTau/Aβ42 had higher receiver operator characteristic - area under the curve (all 0.94), and greater concordance with Aβ-PET (overall percentage agreement ~ 90%), compared with individual biomarkers. Conclusion: Strong concordance between CSF biomarkers and Aβ-PET status was observed overall, including for cognitively normal participants, further strengthening the association between these markers of AD neuropathological burden for both developmental research studies and for use in clinical trials.

Original languageEnglish
Article number36
JournalAlzheimer's Research and Therapy
Issue number1
Publication statusPublished - 31 Mar 2020


Dive into the research topics of 'Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging'. Together they form a unique fingerprint.

Cite this